210 related articles for article (PubMed ID: 19833757)
21. Definition and treatment of lupus flares measured by the BILAG index.
Gordon C; Sutcliffe N; Skan J; Stoll T; Isenberg DA
Rheumatology (Oxford); 2003 Nov; 42(11):1372-9. PubMed ID: 12810926
[TBL] [Abstract][Full Text] [Related]
22. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.
Walz LeBlanc BA; Gladman DD; Urowitz MB
J Rheumatol; 1994 Dec; 21(12):2239-41. PubMed ID: 7699623
[TBL] [Abstract][Full Text] [Related]
23. Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong.
Szeto CC; Mok HY; Chow KM; Lee TC; Leung JY; Li EK; Tsui TK; Yu S; Tam LS
J Rheumatol; 2008 Jun; 35(6):1031-7. PubMed ID: 18398942
[TBL] [Abstract][Full Text] [Related]
24. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
[TBL] [Abstract][Full Text] [Related]
25. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
26. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies.
Narayanan K; Marwaha V; Shanmuganandan K; Shankar S
Med J Armed Forces India; 2010 Apr; 66(2):102-7. PubMed ID: 27365721
[TBL] [Abstract][Full Text] [Related]
28. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
29. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
30. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study.
Barrera-Vargas A; Quintanar-Martínez M; Merayo-Chalico J; Alcocer-Varela J; Gómez-Martín D
Rheumatology (Oxford); 2016 Mar; 55(3):429-35. PubMed ID: 26396262
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus.
Urquizu-Padilla M; Balada E; Cortés F; Pérez EH; Vilardell-Tarrés M; Ordi-Ros J
J Rheumatol; 2009 May; 36(5):953-60. PubMed ID: 19332622
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus.
Ramos-Casals M; Font J; García-Carrasco M; Cervera R; Jiménez S; Trejo O; de la Red G; Sánchez-Tapias JM; Ingelmo M
Arthritis Rheum; 2000 Dec; 43(12):2801-6. PubMed ID: 11145039
[TBL] [Abstract][Full Text] [Related]
34. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
36. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
37. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy.
Bruce IN; Hallett DC; Gladman DD; Urowitz MB
J Rheumatol; 1999 Jul; 26(7):1490-4. PubMed ID: 10405935
[TBL] [Abstract][Full Text] [Related]
38. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
39. Seasonal variations of systemic lupus erythematosus flares in southern France.
Chiche L; Jourde N; Ulmann C; Mancini J; Darque A; Bardin N; Dicostanzo MP; Thomas G; Harlé JR; Vienne J; Loukos H; Bornet C
Eur J Intern Med; 2012 Apr; 23(3):250-4. PubMed ID: 22385883
[TBL] [Abstract][Full Text] [Related]
40. Menopause hormonal therapy in women with systemic lupus erythematosus.
Sánchez-Guerrero J; González-Pérez M; Durand-Carbajal M; Lara-Reyes P; Jiménez-Santana L; Romero-Díaz J; Cravioto MD
Arthritis Rheum; 2007 Sep; 56(9):3070-9. PubMed ID: 17763408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
